Physician profile
Gary P Gross
NPI 1043299639
$7,537.57
in general payments reported to CMS, 2019-2025
26 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $351 · 2021: $354 · 2022: $2,239 · 2023: $1,106 · 2024: $1,524 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.15 |
| Education | $355.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,147.39 | 2019-2025 | |
| Genzyme Corporation | $1,444.40 | 2019-2025 | |
| Janssen Biotech, INC. | $968.63 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $403.32 | 2019-2024 | |
| Pfizer INC. | $389.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $305.38 | 2019-2024 | Winlevi |
| Lilly USA, LLC | $301.85 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $265.10 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $222.50 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $163.78 | 2022-2024 | Dupixent |
| Incyte Corporation | $155.13 | 2023-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $141.56 | 2023-2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $106.25 | 2019 | |
| Amgen INC. | $102.78 | 2019-2024 | Otezla, Enbrel |
| Leo Pharma INC. | $92.88 | 2022-2024 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $56.18 | 2022 | |
| Celgene Corporation | $54.83 | 2019 | |
| Genentech USA, INC. | $39.33 | 2019-2021 | |
| Dermavant Sciences, INC. | $36.35 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.84 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $25.08 | 2019 | |
| Almirall LLC | $21.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.04 | 2025 | Airsupra |
| Paratek Pharmaceuticals, INC. | $16.55 | 2022 | |
| Kerecis Limited | $13.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Musculoskeletal Transplant Foundation INC. | $12.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.